Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a heart drug ease pressure inside the eye?

NCT ID NCT07795762

Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This trial tests whether eplerenone, a drug already approved for other conditions, lowers eye pressure in healthy adults. Researchers will compare eplerenone with a placebo in a crossover design, where each participant takes both treatments at different times. Eye pressure is measured throughout, and blood pressure, kidney function, and potassium levels are monitored for safety. If eplerenone reduces eye pressure, it might offer a new approach to treating glaucoma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eplerenone, an oral medication approved for other conditions, taken as a 50 mg capsule once daily for one week.
What this could lead to
If eplerenone lowers eye pressure, it could point toward a new treatment for glaucoma, a disease where high eye pressure damages vision.
What could go wrong
This is a small, early-phase trial in healthy people, so results may not apply to glaucoma patients. Eplerenone can affect blood pressure, kidney function, and potassium levels, which the study monitors for safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-50 years * No history of glaucoma or ocular hypertension * Baseline intraocular pressure between 10-21 mmHg * Serum creatinine ≤1.3 mg/dL and serum potassium \<4.3 mmol/L * Systolic blood pressure \>110 mmHg Exclusion Criteria: * Use of topical or systemic steroids * Renal disease or hyperkalemia * Concomitant use of strong CYP3A inhibitors, including clarithromycin, erythromycin, ketoconazole, itraconazole, fluconazole, verapamil, diltiazem, or ritonavir * Pregnancy or breastfeeding * Use of medications known to affect intraocular pressure, including topical prostaglandin analogs, topical or systemic beta-blockers, topical alpha-2 agonists, topical or systemic carbonic anhydrase inhibitors, topical Rho-kinase inhibitors, or topical parasympathomimetics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adult are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy adult Intraocular pressure (IOP)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UF Health Eye Center - The Oaks

    Gainesville, Florida, 32605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.